When people hear “nicotinamide,” many first think of serums, skin brightening, and barrier care. Its visibility in skincare is so high that the same assumptions are often carried over when nicotinamide appears in dietary supplements: if topical studies are related to skin tone and barrier function, can oral nicotinamide directly “whiten” or brighten the skin? And because nicotinamide participates in NAD⁺ synthesis, does taking more automatically mean more energy and slower aging?

These associations each capture part of the nicotinamide research landscape, yet they also combine different routes of use, dose levels, and study endpoints. Nicotinamide is first and foremost a form of vitamin B3 and one of the key raw materials the body can use to synthesize nicotinamide adenine dinucleotide (NAD⁺). Understanding it begins with its nutritional identity, followed by a separate look at what topical skin studies, oral nutrition studies, and specific medical studies have actually shown.

1. Start with Its Identity: Nicotinamide Is a Form of Vitamin B3

Vitamin B3 (historically known as vitamin PP or the anti-pellagra factor) refers to a group of compounds with niacin biological activity rather than a single molecule. The two most common forms in nutrition are nicotinic acid and nicotinamide (also called niacinamide). Vitamin B3 ultimately contributes to the formation of the essential coenzymes NAD⁺ and NADP⁺, which support a wide range of biological functions. Chemically, nicotinamide is the amide form of nicotinic acid. Both can provide substrates for the synthesis of NAD⁺ and NADP⁺ and therefore serve as vitamin B3 sources, although their metabolic pathways, dose responses, and adverse-effect profiles are not identical. Dietary tryptophan can also contribute to NAD⁺ and NADP⁺ synthesis through multiple metabolic steps. For this reason, nutritional assessment uses “niacin equivalents” (NE) to combine vitamin B3 sources. One milligram of NE is approximately equivalent to 1 mg of niacin or 60 mg of dietary tryptophan.[1][2]

The body’s basic requirement for vitamin B3 is relatively modest. In the Chinese Dietary Reference Intakes (2023 Edition), the recommended intake of niacin is 15 mg NE/day for adult men and 12 mg NE/day for adult women.[1] Lean meat, poultry, fish, peanuts, and whole grains can all provide vitamin B3 in a typical diet. Severe deficiency can occur when vitamin B3 intake remains inadequate for a prolonged period or when utilization is impaired by factors such as alcohol dependence or malabsorption. The resulting condition, pellagra, is classically summarized by the “3 Ds”: dermatitis, often affecting sun-exposed skin; diarrhea and other gastrointestinal symptoms; and cognitive, emotional, and neurological abnormalities that may progress to dementia and, in severe cases, become life-threatening. These manifestations arise in large part because NAD⁺ and NADP⁺, which depend on vitamin B3 metabolism, are required across many essential biological processes.

This nutritional identity is the starting point for understanding nicotinamide. It can help the body meet its basic requirements for NAD⁺ synthesis. Participating in that synthesis, however, is a different question from whether additional high-dose supplementation can continuously raise a specific biomarker or improve a particular outcome. The former is well established in nutrition science; the latter depends on dose, duration, tissue distribution, and results from human trials.

2. Understand the Basic Physiological Role Before Looking at NAD⁺

After nicotinic acid and nicotinamide enter the body, they can be converted into coenzyme forms such as NAD⁺/NADH and NADP⁺/NADPH. These molecules participate in numerous redox reactions and are central to releasing energy from carbohydrates, fats, and proteins. NADPH also contributes to the synthesis of fatty acids, cholesterol, and other molecules and helps maintain cellular antioxidant capacity.[2][3] The most fundamental and well-established role of vitamin B3 is therefore to support normal energy metabolism and cellular function, rather than serving as a single isolated “anti-aging switch.”

Beyond these basic functions, NAD⁺ also acts as a substrate for several classes of enzymes involved in DNA damage responses, cell signaling, and metabolic regulation. This is one reason NAD⁺ has become a major topic in aging research. As age, inflammation, and metabolic status change, the balance between NAD⁺ production and consumption may shift in certain tissues, prompting researchers to explore interventions with different NAD⁺ precursors.[3][4]

The ability to participate in NAD⁺ synthesis does not mean that more supplementation is always better, and an increase in circulating NAD⁺ cannot automatically be interpreted as improved function in the skin or other organs. Nicotinic acid, nicotinamide, nicotinamide riboside (NR), and nicotinamide mononucleotide (NMN) all relate to the same broad metabolic network, but they differ in structure, metabolic pathways, and doses used in research. Nicotinamide should therefore be evaluated according to its specific form, dose, target population, and study endpoints. NR, NMN, and other NAD⁺-targeted interventions are better addressed as separate topics.[2][4]

3. One Major Area of Skin Research: Topical Nicotinamide

The classic evidence for nicotinamide in skincare focuses on the local skin environment. In 2002, Hakozaki et al. first observed in a melanocyte–keratinocyte co-culture model that nicotinamide reduced melanosome transfer by 35%–68%. The same paper also reported two human studies in Japanese women: 18 participants with facial hyperpigmentation used 5% nicotinamide and vehicle in a paired left-right facial design, while another 120 participants with facial tanning received a sunscreen regimen containing 2% nicotinamide or the corresponding control for 8 weeks. Compared with vehicle, facial pigmentation was significantly reduced and skin lightness significantly increased after 4 weeks in the nicotinamide group.[5] In 2000, Tanno et al. found in cultured normal human keratinocytes that treatment with 1–30 μmol/L nicotinamide for 6 days increased ceramide synthesis by 4.1- to 5.5-fold and also increased the synthesis of glucosylceramide, sphingomyelin, free fatty acids, and cholesterol. In a left-right comparison study involving 12 men with dry skin, 4 weeks of 2% nicotinamide reduced transepidermal water loss by 27% versus the control side, while stratum corneum free fatty acids and ceramides increased by 67% and 34%, respectively.[6] In 2005, Bissett et al. enrolled 50 White women with signs of facial photoaging in a randomized, double-blind, split-face controlled study. Participants applied 5% nicotinamide or vehicle twice daily for 12 weeks. Compared with vehicle, statistically significant improvements were reported in fine lines and wrinkles, hyperpigmented spots, redness, sallowness, and instrument-measured elasticity.[7]

Together, these findings form much of the evidence base for topical nicotinamide in skin brightening, barrier support, and improvement in the visible signs of photoaging. In these studies, the ingredient acts directly on the target tissue, and the concentration, vehicle, and application frequency are designed around local skin exposure. Oral intake follows a very different exposure pathway involving digestion, absorption, first-pass metabolism, tissue distribution, and excretion. Findings such as “reduced melanosome transfer” therefore cannot be converted into an oral skin-brightening mechanism without direct evidence, and topical percentage concentrations cannot be translated into oral doses.

The same ingredient name can appear in both skincare products and nutrition formulas without making the two evidence pathways interchangeable. Distinguishing the route of administration before discussing outcomes is one of the most important boundaries when interpreting nicotinamide research.

4. Another Major Area of Skin Research: Oral Nicotinamide

Research on oral nicotinamide and skin should be read across three levels: cell and ex vivo skin models, animal studies, and human trials. These levels can inform one another, yet each answers a different question. Evidence related to “protection against UV-induced damage” or “reduction of a medical risk” does not by itself demonstrate skin brightening, wrinkle reduction, or improved elasticity.

In 2013, Surjana et al. used HaCaT keratinocytes and ex vivo human skin models to investigate the effect of nicotinamide on DNA repair after simulated solar ultraviolet exposure. They observed that nicotinamide increased both the proportion of cells participating in excision repair and the repair rate per cell, while reducing cyclobutane pyrimidine dimers (CPDs) and 8-oxoguanine (8-oxoG).[8] These findings suggest that nicotinamide may support cellular repair processes after damage, although the evidence remains mechanistic and tissue-level.

At the animal level, studies summarized in Damian’s 2010 review focused mainly on photodamage-related endpoints such as UV-induced immunosuppression and did not report changes in skin melanin or skin tone.[9] These animal findings therefore do not establish that oral nicotinamide brightens skin, reduces wrinkles, or improves elasticity.

Human studies also need to be interpreted according to their specific endpoints. In 2009, Yiasemides et al. conducted two randomized, double-blind, placebo-controlled crossover trials involving 15 and 16 healthy volunteers, respectively. Participants took oral nicotinamide at 1,500 mg/day or 500 mg/day for 1 week. Compared with the placebo period, both doses significantly reduced simulated-sunlight-induced suppression of cutaneous delayed-type hypersensitivity without altering immune responses in unirradiated skin. Both doses were well tolerated, with no notable adverse effects reported.[10] In 2015, Chen et al. conducted a phase III randomized, double-blind, placebo-controlled trial in 386 dermatologically high-risk participants. The nicotinamide group received 500 mg twice daily for 12 months. During the trial, there were no noteworthy differences between groups in the number or types of adverse events.[11] These results support acceptable tolerability within the specific study populations, doses, and observation periods. They do not establish cosmetic benefits or routine photoprotection for the general population.

More recent findings have also been mixed. In 2025, Faisal et al. conducted a before-and-after controlled study in 47 healthy volunteers who took 2,000 mg/day of oral nicotinamide for 30 days. The UVB minimal erythema dose did not change significantly (p=0.533), and thymidine dimers in skin and urine were not significantly reduced.[12] In a 2026 randomized trial by Faisal et al. involving 50 healthy volunteers at the same dose and duration, the UVA minimal erythema dose increased by 26% in the nicotinamide group (p=0.0008), while thymidine dimers in skin and urine again showed no significant reduction.[13] These findings underscore that erythema responses, DNA damage, immune markers, and long-term skin outcomes are distinct endpoints. Routine use of very high-dose nicotinamide cannot be justified simply by assuming that more will produce broader skin benefits.

Overall, oral nicotinamide has been studied in humans in relation to photodamage and dermatologic outcomes, but high-quality evidence directly using skin tone, wrinkles, or elasticity as primary endpoints in the general population remains limited. A more evidence-aligned interpretation is that oral nicotinamide first serves as a nutritional source of vitamin B3 and may influence processes related to UV responses and cellular repair. Current evidence does not establish it as a proven oral skin-whitening, skin-brightening, or anti-wrinkle ingredient. Sun protection remains the most direct measure for preventing photoaging.

5. As an Oral Ingredient, How Should Vitamin B3 Dose and Safety Be Evaluated?

First, identify the ingredient form. Nicotinamide and nicotinic acid are both sources of vitamin B3, but a product should provide more than the vague description “NAD⁺ precursor.” The exact form, amount per serving, purity, impurity profile, stability, and batch testing should also be clear. NR and NMN are different ingredients and their doses and evidence should not be mixed with those of nicotinamide.

Next, consider dietary reference values. According to the Chinese Dietary Reference Intakes (2023 Edition), the recommended nutrient intake (RNI) for niacin is 15 mg NE/day for adult men and 12 mg NE/day for adult women. The RNI is intended to meet the daily needs of most healthy individuals. Tolerable upper intake levels (ULs) also help define the safety boundaries of vitamin B3 supplementation: the adult UL is 15 mg/day for nicotinic acid and 310 mg/day for nicotinamide.[1]

For example, a serving containing 50 mg of nicotinamide provides approximately 3.3 times the RNI for adult men and 4.2 times the RNI for adult women, covering basic nutritional requirements while remaining below the adult nicotinamide UL of 310 mg/day. For generally healthy adults, 50 mg leaves a relatively wide safety margin when total intake from food, multivitamins, and other supplements is also taken into account.

The adverse-effect profiles of the two main vitamin B3 forms should also be distinguished. Higher doses of nicotinic acid can readily cause flushing, warmth, and tingling or itching, whereas nicotinamide generally does not produce the same characteristic flushing response. Nicotinamide has generally been well tolerated in studies using doses from several hundred milligrams to gram levels, but gastrointestinal symptoms such as nausea and diarrhea, as well as changes in liver enzymes, may still occur as dose and duration increase. Long-term use at high doses warrants professional assessment.[14][15] Persistent rash, itching, or other unusual reactions after supplementation should also prompt discontinuation and consultation with a qualified professional rather than further self-escalation of the dose.

The ingredient’s role within the overall formula also matters. As a source of vitamin B3, nicotinamide can work alongside other B vitamins to support normal energy metabolism, while formulation should still avoid simply stacking unnecessarily high doses. If the goal is skin-state management, upstream factors such as sun protection, sleep, protein and micronutrient intake, smoking, and blood glucose management should also be considered. A single ingredient is unlikely to cover every pathway involved in pigmentation, barrier function, oxidative stress, and tissue renewal.

Finally, consider duration and the intended population. Nutritional supplementation is best evaluated in the context of dietary gaps and long-term intake patterns. Regimens in the several-hundred-milligram range or higher, as well as use in people with chronic conditions, during pregnancy or breastfeeding, or alongside medications, should be discussed with a physician or qualified nutrition professional first. Stable physiological function depends on coordination across multiple pathways. This is also why SUPER-SYN places particular emphasis on where an ingredient fits within a broader biological system and which part of that system it is intended to support.

Conclusion: Returning from Popular Labels to Nutritional Identity

Nicotinamide appears in skincare, nutrition, and NAD⁺ research because it has a broad biological role—and that same breadth makes it easy to extrapolate evidence across contexts. Topical evidence helps explain local skin pathways, oral evidence first supports its nutritional identity as vitamin B3, and specific high-dose studies must always retain their population, dose, and endpoint limitations.

What matters most is the form in which nicotinamide enters the body, how much is used, how long it is used, and what the evidence actually measured. A single label such as “whitening” or “anti-aging” cannot capture these differences. Once those questions are made clear, nicotinamide can be understood less as a familiar trend ingredient and more as a nutritional ingredient that can be evaluated accurately, used appropriately, and assessed over the long term.

References

  1. Chinese Nutrition Society. Chinese Dietary Reference Intakes (2023 Edition). Beijing: People’s Medical Publishing House; 2023.
  2. Bogan KL, Brenner C. Nicotinic acid, nicotinamide, and nicotinamide riboside: A molecular evaluation of NAD⁺ precursor vitamins in human nutrition. Annual Review of Nutrition. 2008;28:115-130. DOI: 10.1146/annurev.nutr.28.061807.155443.
  3. Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD⁺ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology. 2021;22(2):119-141. DOI: 10.1038/s41580-020-00313-x.
  4. Migaud ME, Ziegler M, Baur JA. Regulation of and challenges in targeting NAD⁺ metabolism. Nature Reviews Molecular Cell Biology. 2024;25(10):822-840. DOI: 10.1038/s41580-024-00752-w.
  5. Hakozaki T, Minwalla L, Zhuang J, et al. The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. British Journal of Dermatology. 2002;147(1):20-31. DOI: 10.1046/j.1365-2133.2002.04834.x.
  6. Tanno O, Ota Y, Kitamura N, Katsube T, Inoue S. Nicotinamide increases biosynthesis of ceramides as well as other stratum corneum lipids to improve the epidermal permeability barrier. British Journal of Dermatology. 2000;143(3):524-531. DOI: 10.1111/j.1365-2133.2000.03705.x.
  7. Bissett DL, Oblong JE, Berge CA. Niacinamide: A B vitamin that improves aging facial skin appearance. Dermatologic Surgery. 2005;31(7 Pt 2):860-865. DOI: 10.1111/j.1524-4725.2005.31732.
  8. Surjana D, Halliday GM, Damian DL. Nicotinamide enhances repair of ultraviolet radiation-induced DNA damage in human keratinocytes and ex vivo skin. Carcinogenesis. 2013;34(5):1144-1149. DOI: 10.1093/carcin/bgt017.
  9. Damian DL. Photoprotective effects of nicotinamide. Photochemical & Photobiological Sciences. 2010;9(4):578-585. DOI: 10.1039/b9pp00146h.
  10. Yiasemides E, Sivapirabu G, Halliday GM, Park J, Damian DL. Oral nicotinamide protects against ultraviolet radiation-induced immunosuppression in humans. Carcinogenesis. 2009;30(1):101-105. DOI: 10.1093/carcin/bgn248.
  11. Chen AC, Martin AJ, Choy B, et al. A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. New England Journal of Medicine. 2015;373(17):1618-1626. DOI: 10.1056/NEJMoa1506197.
  12. Faisal A, Philipsen PA, Lerche CM, et al. Changes in ultraviolet B radiation-induced DNA damage and erythema after oral nicotinamide and polypodium leucotomos in healthy volunteers: an intraindividual controlled trial. Photochemical & Photobiological Sciences. 2025;24(11):1951-1958. DOI: 10.1007/s43630-025-00807-7.
  13. Faisal A, Lerche CM, Douki T, et al. Changes in ultraviolet A radiation-induced thymidine dimers and erythema after oral nicotinamide or polypodium leucotomos extract in healthy volunteers: a randomized intraindividual trial. Photochemical & Photobiological Sciences. 2026;25(5):845-852. DOI: 10.1007/s43630-026-00884-2.
  14. Knip M, Douek IF, Moore WP, et al. Safety of high-dose nicotinamide: A review. Diabetologia. 2000;43(11):1337-1345. DOI: 10.1007/s001250051536.
  15. Hwang ES, Song SB. Possible adverse effects of high-dose nicotinamide: Mechanisms and safety assessment. Biomolecules. 2020;10(5):687. DOI: 10.3390/biom10050687.